HUP0102900A2 - Javított szilárd fázisú peptidszintézis és a szintézisben alkalmazható anyagok - Google Patents
Javított szilárd fázisú peptidszintézis és a szintézisben alkalmazható anyagokInfo
- Publication number
- HUP0102900A2 HUP0102900A2 HU0102900A HUP0102900A HUP0102900A2 HU P0102900 A2 HUP0102900 A2 HU P0102900A2 HU 0102900 A HU0102900 A HU 0102900A HU P0102900 A HUP0102900 A HU P0102900A HU P0102900 A2 HUP0102900 A2 HU P0102900A2
- Authority
- HU
- Hungary
- Prior art keywords
- amino acid
- amino acids
- amino
- synthesis
- peptide
- Prior art date
Links
- 238000010647 peptide synthesis reaction Methods 0.000 title abstract 2
- 239000007790 solid phase Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000008575 L-amino acids Chemical class 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 150000008574 D-amino acids Chemical group 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Prostheses (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A találmány tárgya eljárás az (I) általános képletű peptidek, aképletben AA jelentése L- vagy D-aminosav maradék, X jelentésehidrogénatom vagy amino-védőcsoport, Y jelentése hidroxil- vagyaminocsoport vagy 3 és 9 közötti számú aminosav-maradékot tartalmazóaminosav szekvencia és n értéke 2-nél nagyobb egész szám -előállítására szilárd fázisú szintézissel, ahol egy N-a-védett ésadott esetben oldalláncban védett reaktív származék formájú C-terminális aminosavat egy szilárd hordozóhoz vagy egy polimerhezkapcsolnak adott esetben egy közvetítőcsoporton át, ezután az N-a-védőcsoportot eltávolítják, majd a peptid szekvenciát képező továbbiaminosavakat lépésenként kapcsolják vagy peptidfragmensként kapcsoljákés a peptidet lehasítják a szilárd hordozóról. Az eljárás során olyanelőszekvenciát állítanak elő, amely 3 és 9 közötti, előnyösen 5 és 7közötti egymástól függetlenül kiválasztott természetes L-aminosavból -amely természetes L-aminosavak a kapcsolási lépésben védett oldalláncfunkciócsoportokat tartalmaznak, és amely L-aminosavak Pa vonzásifaktora 0,57 és Pb vonzási faktora 1,10 - vagy az ezeknek megfelelő D-aminosavakból származó aminosav-maradékokat tartalmaz. A találmánykiterjed a szilárd fázisú peptidszintézisben alkalmazottköztitermékekre. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK97196 | 1996-09-09 | ||
| DK0971/96 | 1996-09-09 | ||
| PCT/DK1997/000375 WO1998011125A1 (en) | 1996-09-09 | 1997-09-09 | Improved solid-phase peptide synthesis and agent for use in such synthesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0102900A2 true HUP0102900A2 (hu) | 2002-01-28 |
| HUP0102900A3 HUP0102900A3 (en) | 2002-02-28 |
| HU230354B1 HU230354B1 (hu) | 2016-02-29 |
Family
ID=8099561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0102900A HU230354B1 (hu) | 1996-09-09 | 1997-09-09 | Javított szilárd fázisú peptidszintézis és a szintézisben alkalmazható anyagok |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7348404B2 (hu) |
| EP (1) | EP0929567B1 (hu) |
| JP (1) | JP4405594B2 (hu) |
| AT (1) | ATE290014T1 (hu) |
| AU (1) | AU723268B2 (hu) |
| CA (1) | CA2265900C (hu) |
| CZ (1) | CZ295838B6 (hu) |
| DE (1) | DE69732640T2 (hu) |
| DK (1) | DK0929567T3 (hu) |
| ES (1) | ES2239364T3 (hu) |
| HU (1) | HU230354B1 (hu) |
| IL (1) | IL128829A (hu) |
| PT (1) | PT929567E (hu) |
| WO (1) | WO1998011125A1 (hu) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999046283A1 (en) * | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| US7550425B2 (en) | 2000-06-16 | 2009-06-23 | Zealand Pharma A/S | Diuretic peptide conjugates |
| PT1737889E (pt) | 2004-10-19 | 2010-12-13 | Lonza Ag | Método para síntese de péptidos em fase sólida |
| KR101200227B1 (ko) | 2005-05-04 | 2012-11-13 | 질랜드 파마 에이/에스 | 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체 |
| GB0514071D0 (en) | 2005-07-07 | 2005-08-17 | Zealand Pharma As | N- or C- terminally modified small peptides |
| JPWO2007060860A1 (ja) * | 2005-11-22 | 2009-05-07 | 学校法人日本大学 | ピロールイミダゾールポリアミドの固相自動合成 |
| DK1966130T3 (da) | 2005-12-23 | 2014-02-10 | Zealand Pharma As | Modificerede lysin-mimetiske forbindelser |
| KR100859972B1 (ko) | 2006-02-20 | 2008-09-25 | 이화여자대학교 산학협력단 | 막투과 단백질 도메인 펩타이드 |
| WO2007114454A1 (ja) * | 2006-03-29 | 2007-10-11 | Otsuka Chemical Co., Ltd. | ペプチドのチオエステル化合物の製造方法 |
| JP5819586B2 (ja) | 2006-11-08 | 2015-11-24 | ジーランド ファーマ アクティーゼルスカブ | 選択的グルカゴン様ペプチド−２（ｇｌｐ−２）類似体 |
| WO2008152403A1 (en) | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Glucagon analogues |
| BRPI0823377A2 (pt) | 2008-12-15 | 2016-09-27 | Zealand Pharma As | análogos de glucagon |
| DK2370460T3 (da) | 2008-12-15 | 2014-08-04 | Zealand Pharma As | Glucagon analoger |
| MX2011006313A (es) | 2008-12-15 | 2011-09-27 | Zealand Pharma As | Analogos de glucagon. |
| BRPI0823379A2 (pt) | 2008-12-15 | 2015-07-14 | Zealand Pharma As | Análogos de glucagon |
| DK2454282T3 (en) | 2009-07-13 | 2015-05-04 | Zealand Pharma As | acetylated glucagonanaloger |
| US9089538B2 (en) | 2010-04-27 | 2015-07-28 | Zealand Pharma A/S | Peptide conjugates of GLP-1 receptor agonists and gastrin and their use |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| EP2585482B1 (en) | 2010-06-24 | 2019-03-27 | Zealand Pharma A/S | Glucagon analogues |
| EP2665487A1 (en) | 2011-01-20 | 2013-11-27 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
| JP6359972B2 (ja) | 2011-11-03 | 2018-07-18 | ジーランド ファーマ アクティーゼルスカブ | Ｇｌｐ−１受容体アゴニストペプチドガストリンコンジュゲート |
| CN104144696A (zh) | 2011-12-23 | 2014-11-12 | 西兰制药公司 | 胰高血糖素类似物 |
| WO2013098408A1 (en) | 2011-12-30 | 2013-07-04 | Zealand Pharma A/S | Glucagon and cck receptor agonist peptide conjugates |
| EP2809339A2 (en) | 2012-02-03 | 2014-12-10 | Zealand Pharma A/S | Ghrelin analogues |
| KR102184241B1 (ko) | 2012-05-03 | 2020-12-01 | 질랜드 파마 에이/에스 | Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법 |
| AU2013255752B2 (en) | 2012-05-03 | 2017-11-09 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| CN104662038B (zh) | 2012-07-23 | 2018-11-06 | 西兰制药公司 | 胰高血糖素类似物 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| LT2970487T (lt) | 2013-03-12 | 2020-05-11 | Molecular Templates, Inc. | Citotoksiniai baltymai, apimantys tikslinių ląstelių rišimosi sritis ir shiga toksino subvienetų sritis, skirtas selektyviam tam tikrų rūšių ląstelių žudymui |
| US9169287B2 (en) | 2013-03-15 | 2015-10-27 | Massachusetts Institute Of Technology | Solid phase peptide synthesis processes and associated systems |
| US9695214B2 (en) | 2013-03-15 | 2017-07-04 | Massachusetts Institute Of Technology | Solid phase peptide synthesis processes and associated systems |
| SG11201506804VA (en) | 2013-03-21 | 2015-09-29 | Sanofi Aventis Deutschland | Synthesis of hydantoin containing peptide products |
| WO2014147129A1 (en) | 2013-03-21 | 2014-09-25 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| KR102569036B1 (ko) | 2013-10-17 | 2023-08-23 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
| CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
| US10131702B2 (en) | 2013-11-06 | 2018-11-20 | Zealand Pharma A/S | Glucagon-GLP-1-GIP triple agonist compounds |
| US10435474B2 (en) | 2013-12-24 | 2019-10-08 | Ossianix, Inc. | Baff selective binding compounds and related methods |
| CN106103489B (zh) | 2014-01-27 | 2020-10-02 | 分子模板公司 | Mhc i类表位递送多肽 |
| WO2017019623A2 (en) | 2015-07-26 | 2017-02-02 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
| ES2864124T3 (es) | 2014-03-11 | 2021-10-13 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
| SI3604333T1 (sl) | 2014-03-11 | 2021-08-31 | Molecular Templates, Inc. | Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38 |
| JP6735237B2 (ja) | 2014-06-11 | 2020-08-05 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | プロテアーゼ切断耐性、志賀毒素ａサブユニットエフェクターポリペプチド及びそれを含む細胞標的化分子 |
| US10479990B2 (en) | 2014-06-26 | 2019-11-19 | Ossianix, Inc. | Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds |
| RU2716985C2 (ru) | 2014-10-29 | 2020-03-17 | Зилэнд Фарма А/С | Соединения-агонисты gip и способы |
| EP3218411B1 (en) | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
| AU2016215205B2 (en) | 2015-02-05 | 2021-10-21 | Molecular Templates, Inc. | Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
| MX2017011182A (es) | 2015-03-18 | 2018-06-06 | Zealand Pharma As | Analogos de amilina. |
| GB201506380D0 (en) | 2015-04-15 | 2015-05-27 | Serodus Asa | Materials and methods for treatment of pulmonary hypertension |
| RU2735762C2 (ru) | 2015-04-16 | 2020-11-06 | Зилэнд Фарма А/С | Ацилированный аналог глюкагона, его применение и способы получения |
| PT3303373T (pt) | 2015-05-30 | 2020-07-14 | Molecular Templates Inc | Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas |
| EP3350197A4 (en) | 2015-09-17 | 2019-04-24 | Massachusetts Institute of Technology | METHODS AND SYSTEMS FOR SYNTHESIZING SOLID-STATE PEPTIDE |
| AU2017311040B2 (en) | 2016-08-06 | 2023-08-31 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
| US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
| JP2020500890A (ja) | 2016-12-09 | 2020-01-16 | ジーランド・ファーマ・ア／エス | Ｇｌｐ−１／ｇｌｐ−２二重アゴニスト |
| WO2018104558A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| AU2017371516C1 (en) | 2016-12-09 | 2021-09-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
| WO2018104559A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| WO2018103868A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| AU2018213194B2 (en) | 2017-01-25 | 2023-01-12 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes |
| WO2019089395A1 (en) | 2017-11-02 | 2019-05-09 | Ossianix, Inc. | Improved tfr-selective binding peptides capable of crossing the blood brain barrier |
| AU2019228639A1 (en) | 2018-02-27 | 2020-09-17 | Zp Spv 3 K/S | Compstatin analogues and their medical uses |
| KR20200143634A (ko) | 2018-04-17 | 2020-12-24 | 몰레큘러 템플레이츠, 인코퍼레이션. | 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자 |
| WO2019246288A1 (en) | 2018-06-22 | 2019-12-26 | Ossianix, Inc. | Anti-cd98hc vnars for crossing the blood brain barrier and type iv vnar libraries |
| US20210395381A1 (en) | 2018-09-14 | 2021-12-23 | Ossianix, Inc. | Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| CN113454108A (zh) | 2019-01-23 | 2021-09-28 | 米伦纽姆医药公司 | 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白 |
| US20230212227A1 (en) | 2019-06-14 | 2023-07-06 | Zealand Pharma A/S | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| EP4272751A3 (en) | 2019-08-27 | 2024-02-14 | Zp Spv 3 K/S | Compstatin analogues and their medical uses |
| WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
| TW202116350A (zh) | 2019-09-20 | 2021-05-01 | 丹麥商西蘭製藥公司 | Kv1.3阻斷劑 |
| US20210155671A1 (en) | 2019-11-24 | 2021-05-27 | Molecular Templates, Inc. | Uses of cd20-binding molecules and additional therapeutic agents |
| EP4126003A1 (en) | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| WO2021198195A1 (en) | 2020-03-30 | 2021-10-07 | Zealand Pharma A/S | Agonist combination |
| EP4182023A1 (en) | 2020-07-16 | 2023-05-24 | Zp Spv 3 K/S | Inhibitors of complement factor c3 and their medical uses |
| WO2022103769A1 (en) | 2020-11-11 | 2022-05-19 | Ossianix, Inc. | High affinity human and monkey specific tfr-1 vnars |
| US20230405088A1 (en) | 2020-12-16 | 2023-12-21 | Zealand Pharma A/S | Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists |
| CN116710114A (zh) | 2020-12-16 | 2023-09-05 | 西兰制药公司 | Glp-1/glp-2双重激动剂的药物组合物 |
| IL301892A (en) | 2020-12-16 | 2023-06-01 | Zealand Pharma As | Drug composition of dual GLP-1/GLP-2 agonists |
| WO2022175410A1 (en) | 2021-02-18 | 2022-08-25 | Zealand Pharma A/S | Composition for treating short bowel syndrome |
| US20220306700A1 (en) | 2021-03-17 | 2022-09-29 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| JP2024511449A (ja) | 2021-03-23 | 2024-03-13 | ジーランド ファーマ エー／エス | Ｋｖ１．３遮断薬 |
| WO2022260877A1 (en) | 2021-06-07 | 2022-12-15 | Ossianix, Inc. | Shark vnars for treating covid-19 |
| WO2022262837A1 (zh) | 2021-06-18 | 2022-12-22 | 北京拓界生物医药科技有限公司 | 胰高血糖素类似物及其医药用途 |
| AU2022329980A1 (en) | 2021-08-17 | 2024-02-15 | Ossianix, Inc. | Deimmunized vnar domains and scaffolds |
| KR20240058121A (ko) | 2021-09-03 | 2024-05-03 | 질랜드 파마 에이/에스 | 투여 용법 |
| WO2023099669A1 (en) | 2021-12-01 | 2023-06-08 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2024068848A1 (en) | 2022-09-28 | 2024-04-04 | Zealand Pharma A/S | Methods for treating obesity |
| WO2024083919A1 (en) | 2022-10-18 | 2024-04-25 | Zealand Pharma A/S | Inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5116666A (hu) | 1974-07-30 | 1976-02-10 | Shionogi Seiyaku Kk | |
| US5021550A (en) * | 1986-10-07 | 1991-06-04 | Thomas Jefferson University | Method for preventing deletion sequences in solid phase synthesis |
| JP2807287B2 (ja) | 1989-10-13 | 1998-10-08 | 株式会社医学生物学研究所 | ペプチドおよびその用途 |
| CA2170030A1 (en) | 1993-09-14 | 1995-03-23 | Robert A. Lazarus | Pharmaceutical compositions containing ecotin and homologs thereof |
| US7176282B1 (en) | 1996-09-09 | 2007-02-13 | Zealand Pharma A/S | Solid-phase peptide synthesis and agent for use in such synthesis |
| WO1999046283A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
-
1997
- 1997-09-09 CZ CZ1999803A patent/CZ295838B6/cs not_active IP Right Cessation
- 1997-09-09 WO PCT/DK1997/000375 patent/WO1998011125A1/en active IP Right Grant
- 1997-09-09 PT PT97939974T patent/PT929567E/pt unknown
- 1997-09-09 DE DE69732640T patent/DE69732640T2/de not_active Expired - Lifetime
- 1997-09-09 HU HU0102900A patent/HU230354B1/hu not_active IP Right Cessation
- 1997-09-09 DK DK97939974T patent/DK0929567T3/da active
- 1997-09-09 IL IL12882997A patent/IL128829A/xx not_active IP Right Cessation
- 1997-09-09 CA CA002265900A patent/CA2265900C/en not_active Expired - Lifetime
- 1997-09-09 AU AU41993/97A patent/AU723268B2/en not_active Ceased
- 1997-09-09 ES ES97939974T patent/ES2239364T3/es not_active Expired - Lifetime
- 1997-09-09 JP JP51316698A patent/JP4405594B2/ja not_active Expired - Fee Related
- 1997-09-09 AT AT97939974T patent/ATE290014T1/de active
- 1997-09-09 EP EP97939974A patent/EP0929567B1/en not_active Expired - Lifetime
-
2006
- 2006-06-19 US US11/455,388 patent/US7348404B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2265900C (en) | 2007-07-31 |
| JP4405594B2 (ja) | 2010-01-27 |
| AU4199397A (en) | 1998-04-02 |
| DE69732640T2 (de) | 2006-01-12 |
| WO1998011125A1 (en) | 1998-03-19 |
| EP0929567B1 (en) | 2005-03-02 |
| CA2265900A1 (en) | 1998-03-19 |
| IL128829A0 (en) | 2000-01-31 |
| DK0929567T3 (da) | 2005-06-27 |
| DE69732640D1 (de) | 2005-04-07 |
| EP0929567A1 (en) | 1999-07-21 |
| JP2001500134A (ja) | 2001-01-09 |
| AU723268B2 (en) | 2000-08-24 |
| CZ295838B6 (cs) | 2005-11-16 |
| HU230354B1 (hu) | 2016-02-29 |
| CZ80399A3 (cs) | 1999-08-11 |
| ATE290014T1 (de) | 2005-03-15 |
| IL128829A (en) | 2005-08-31 |
| US7348404B2 (en) | 2008-03-25 |
| HUP0102900A3 (en) | 2002-02-28 |
| US20070004905A1 (en) | 2007-01-04 |
| ES2239364T3 (es) | 2005-09-16 |
| PT929567E (pt) | 2005-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0102900A2 (hu) | Javított szilárd fázisú peptidszintézis és a szintézisben alkalmazható anyagok | |
| SU1651787A3 (ru) | Способ получени полипептида, обладающего свойствами фактора высвобождени гормона роста | |
| HU903740D0 (en) | Process for the production of new proteins | |
| KR100237126B1 (ko) | 펩티드 유사체의 신속한 합성 및 검색방법 | |
| GR3031169T3 (en) | Cd8 binding domain peptides. | |
| WO1999026964A1 (en) | LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES | |
| KR870007203A (ko) | 펩타이드를 제조하는 방법 | |
| ATE508138T1 (de) | N- und/oder c-terminal mit kurzen geladenen peptidsequenzen modifizierte peptide | |
| CA2439598A1 (en) | Modified derivatives of cck-8 | |
| EP0751148A3 (en) | D-amino acid substitution analogues of magainin peptides | |
| HU185321B (en) | Process for preparing pharmacologically active ancephaline analogues | |
| Nishiuchi et al. | Nin-Cyclohexyloxycarbonyl group as a new protecting group for tryptophan | |
| HU185229B (en) | Process for preparing pharmaceutically active peptides and acetates thereof | |
| IL156799A (en) | Peptides related to the GP120 viral protein and their uses | |
| ATE50267T1 (de) | Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren. | |
| HU222051B1 (hu) | Biciklusos tachikinin antagonisták, eljárás előállításukra és alkalmazásuk | |
| HUP0203504A2 (hu) | Immunterápiás alkalmazásra szolgáló módosított peptidek és peptid-mimetikumok | |
| Wakamiya et al. | An Efficient Procedure for Synthesis of Phosphopeptides through the Benzyl Phosphate-Protection by the Boc Mode Solid-Phase Method. | |
| CA1090784A (en) | Synthesis for peptides | |
| Nishiyama et al. | Cyclohexyl ether as a new hydroxy-protecting group for serine in solid-phase peptide synthesis | |
| EP1032585A4 (en) | DEOXYHYPUSIN REAGENT AND PEPTIDE | |
| AP546A (en) | Peptides for inhibiting pepsin release. | |
| CA2405724A1 (en) | Substance p analogs for the treatment of cancer | |
| EP0463070B1 (en) | A process for producing pentapeptides and intermediates for use in the synthesis | |
| HU188618B (en) | Process for producing biologically active analogues of enkephaline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NF4A | Restoration of patent protection | ||
| MM4A | Lapse of definitive patent protection due to non-payment of fees |